Alpha 1 Antitrypsin Deficiency Treatment Market Expert Reviews & Analysis 2020 Along With Study Reports

The report presents an in-depth assessment of the Alpha 1 Antitrypsin Deficiency Treatment including enabling technologies, key trends, market drivers, challenges, standardization, regulatory landscape, deployment models, operator case studies, opportunities, future roadmap, value chain, ecosystem player profiles and strategies. The report also presents forecasts for Alpha 1 Antitrypsin Deficiency Treatment investments from 2020 till 2026.

The global Alpha 1 Antitrypsin Deficiency Treatment market is valued at 1190 million US$ in 2018 and will reach 2560 million US$ by the end of 2025, growing at a CAGR of 10.1% during 2019-2025.

Key players cited in the report: Pfizer, Baxter, AstraZeneca, Grifols, Teva Pharmaceutical Industries, Boehringer Ingelheim, Kamada Ltd,GlaxoSmithKline, CSL Behring, Shire, LFB Biomedicaments, Abeona Therapeutics, Biogen, Applied Genetic Technologies, Baxalta, Arrowhead Research Corporation, ProBioGen, Chiesi Pharmaceuticals, Curaxys, ProMetic Life Sciences Other.

Click the link to get a Sample Copy of the Report:
https://www.marketinsightsreports.com/reports/06191303691/global-alpha-1-antitrypsin-deficiency-treatment-market-insights-forecast-to-2025/inquiry?&Mode=54

Competitive Landscape
Key players of the global Alpha 1 Antitrypsin Deficiency Treatment market are profiled on the basis of various factors, which include recent developments, business strategies, financial strength, weaknesses, and main business. The Alpha 1 Antitrypsin Deficiency Treatment report offers a special assessment of top strategic moves of leading players such as merger and acquisition, collaboration, new product launch, and partnership.

Market size by Product
Augmentation Therapy
Bronchodilators
Corticosteroids
Oxygen Therapy
Market size by End User
Hospitals
Specialty Clinics
Pharmacies

Recent Development:

DEC 17, 2019,LEXINGTON, Mass.--(BUSINESS WIRE)-- Dicerna(TM) Pharmaceuticals, Inc. (Nasdaq: DRNA) (the "Company" or "Dicerna"), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the European Commission (EC) has granted orphan drug designation to Dicerna's DCR-A1AT for the treatment of congenital alpha-1 antitrypsin (A1AT) deficiency based on a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA). A1AT deficiency is a genetic disorder that can cause liver disease in children and adults, leading to complications such as fatigue, jaundice or unintended weight loss. Patients with A1AT deficiency are also at risk of serious or life-threatening conditions such as cirrhosis, liver failure and hepatocellular carcinoma, and may develop lung disease.1

"We are gratified to see regulators recognize the urgent need for the development of a safe and effective therapy for treatment of alpha-1 antitrypsin deficiency," said Ralf Rosskamp, M.D., chief medical officer of Dicerna. "This orphan drug designation from the European Commission acknowledges the needs of this underserved patient population, and we look forward to continuing to investigate DCR-A1AT's potential in our recently initiated DCR-A1AT development program that includes a Phase 1/2 study now underway in healthy volunteers."

In June 2019, the Company submitted a clinical trial application to the Swedish Medical Products Agency for DCR-A1AT for the treatment of patients with A1AT deficiency-associated liver disease and began enrolling healthy volunteers in the Phase 1/2 trial of DCR-A1AT (EudraCT number 2019-001999-11) in the fourth quarter of 2019.

Regional Segments Analysis:
The Middle East and Africa (GCC Countries and Egypt.)
North America(the United States, Mexico, and Canada.)
South America (Brazil etc.)
Europe(Turkey, Germany, Russia UK, Italy, France, etc.)
Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia.)

Browse Full Report and TOC:
https://www.marketinsightsreports.com/reports/06191303691/global-alpha-1-antitrypsin-deficiency-treatment-market-insights-forecast-to-2025?Mode=54

Highlights of TOC:
Market Overview: It starts with product overview and scope of the global Alpha 1 Antitrypsin Deficiency Treatment market and later gives consumption and production growth rate comparisons by application and product respectively. It also includes a glimpse of the regional study and Alpha 1 Antitrypsin Deficiency Treatment market size analysis for the review period 2014-2025.
Company Profiles: Each company profiled in the report is assessed for its market growth keeping in view vital factors such as price, Alpha 1 Antitrypsin Deficiency Treatment market gross margin, revenue, production, markets served, main business, product specifications, applications, and introduction, areas served, and production sites.
Manufacturing Cost Analysis: It includes industrial chain analysis, manufacturing process analysis, the proportion of manufacturing cost structure, and the analysis of key raw materials.
Market Dynamics: Readers are provided with a comprehensive analysis of Alpha 1 Antitrypsin Deficiency Treatment market challenges, influence factors, drivers, opportunities, and trends.
Market Forecast: Here, the Alpha 1 Antitrypsin Deficiency Treatment report provides consumption forecast by application, price, revenue, and production forecast by product, consumption forecast by region, production forecast by region, and production and revenue forecast.

Browse More Related Report:
Global Swedish Porphyria Treatment Market Size, Status and Forecast 2020-2026-
https://www.marketinsightsreports.com/reports/04031948262/global-swedish-porphyria-treatment-market-size-status-and-forecast-2020-2026?mode=54
Global Arginase Deficiency Treatment Market 2019 By Manufacturers, Regions, Type And Application, Forecast To 2024
https://www.marketinsightsreports.com/reports/03061136790/global-arginase-deficiency-treatment-market-2019-by-manufacturers-regions-type-and-application-forecast-to-2024?mode=54
Global Vitamin D Deficiency Treatment Market 2019 By Company, Regions, Type And Application, Forecast To 2024
https://www.marketinsightsreports.com/reports/05301271379/global-vitamin-d-deficiency-treatment-market-2019-by-company-regions-type-and-application-forecast-to-2024?mode=54

How we have factored the effect of Covid-19 in our report:
All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

: contact@marketinsightsreports.com
Address : 4893, Pepper drive, Harrisburg ,NC 28075,United States
Address : 202, Business Square, Tilak Road, Pune, Maharashtra 411030
Contact Number : +1 (704) 266-3234

MarketInsightsReportsprovides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, trends, and strategic recommendations.

This release was published on openPR.